Emma Dean

15PUBLICATIONS
162CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsAvionics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Sep 30, 2026
Safety and efficacy of ceralasertib, an ATR kinase inhibitor, combined with olaparib: dose escalation in advanced solid tumours and dose expansion in advanced breast cancer.

|Sep 21, 2026
Safety and Efficacy of Ceralasertib plus Olaparib for Advanced/Metastatic Triple-Negative Breast Cancer in Three Molecular Strata: The Phase II VIOLETTE Study.

|Jun 01, 2026
Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study.

|Apr 21, 2026
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.

|Mar 31, 2026
Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.

Juanita S Lopez, Kevin J Harrington, Seock-Ah Im

|Sep 16, 2025
Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP).

Irene Tsung, David C Smith, Elisabeth I Heath

Pageof 3

Frequent Collaborators

4 joint publications

Sonia Iyer

3 joint publications

Sophie Postel-Vinay

3 joint publications

Matthew G Krebs

3 joint publications

Seock-Ah Im